FDA May Speed Drug Ad Review For Fee

Law360, New York (November 21, 2006, 12:00 AM EST) -- The U.S. Food and Drug Administration has reached a tentative agreement with pharmaceutical companies that would allow companies to pay the FDA fees to inspect their television ads in exchange for a speedier review.

Fees from the deal would help pay for the new staff needed to review the industry’s TV ads, the Wall Street Journal reported.

The FDA's Division of Drug Marketing, Advertising and Communications was recently restructured to address the ever-increasing workload of reviewing direct-to-consumer advertising materials.

In early September, the original DTC review...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.